Trial Profile
Phase Ib Study of Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Patients With Metastatic Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Rebastinib (Primary) ; Eribulin; Paclitaxel
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Adverse reactions
- 23 Mar 2022 Status changed from recruiting to discontinued.
- 09 Aug 2021 Planned End Date changed from 1 Dec 2021 to 1 Feb 2022.
- 09 Aug 2021 Planned primary completion date changed from 1 Jul 2021 to 1 Feb 2022.